Additional FDA-approved medication for brain tumor treatment
| Medication | Tumor type | Mechanism of action |
|---|---|---|
| Evorlimus | Subependymal giant cell astrocytoma (associated with tuberous sclerosis), potential applications to pediatric tumors to include DIPG, peripheral primitive neuroectodermal tumors, anaplastic astrocytomas, and ependymomas [21] | Immunosuppressive macrolide that works in T-cells in response to alloantigen to stop growth-driven transduction signals [22] |
| Belzutifan | VHL associated tumors like hemangioblastoma [23] | HIF-2α inhibitor thus decreasing tumorigenesis [24] |
DIPG: diffuse intrinsic pontine gliomas; VHL: Von Hippel-Lindau; HIF-2α: hypoxia-inducible factor-2alpha
BLW: Conceptualization, Supervision, Writing—review & editing. MM: Conceptualization, Project administration, Visualization. MS, AS and MM: Writing—original draft, Writing—review & editing
The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Uniformed Services University of the Health Sciences, the Department of Defense, or the U.S. Government.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2023.